Last reviewed · How we verify
Remi 0.1
Remi 0.1, developed by Dokuz Eylul University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a significant barrier to generic competition until 2028. The lack of detailed revenue and clinical trial data poses a primary risk, making it challenging to assess its commercial performance and therapeutic efficacy.
At a glance
| Generic name | Remi 0.1 |
|---|---|
| Also known as | remifentanil, Ultiva, Glaxo Wellcome, Marly-le-Roi, France |
| Sponsor | Dokuz Eylul University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dexmedetomidine and Remifentanil in NORA (PHASE4)
- Remifentanil on Hemodynamic Response to Anesthesia Induction (PHASE4)
- Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remi 0.1 CI brief — competitive landscape report
- Remi 0.1 updates RSS · CI watch RSS
- Dokuz Eylul University portfolio CI